Rutter Jill, Wilcox Christopher R, Odeh Nour, Muller Ingrid, Clark Tristan W, Little Paul, Davies Firoza, McGavin John, Francis Nick
Primary Care Research Centre, University of Southampton, Southampton, UK.
Primary Care Research Centre, University of Southampton, Southampton, UK
BJGP Open. 2024 Oct 29;8(3). doi: 10.3399/BJGPO.2024.0024. Print 2024 Oct.
FebriDx is a single-use, analyser-free, point-of-care test with markers for bacterial (C-reactive protein [CRP]) and viral (myxovirus resistance protein A [MxA]) infection, measured on a finger-prick blood sample.
As part of a larger feasibility study, we explored the views of healthcare professionals (HCPs) and patients on the use of FebriDx to safely reduce antibiotic prescriptions for lower respiratory tract infections (LRTIs) in primary care.
DESIGN & SETTING: Remote semi-structured qualitative interviews were conducted in South England.
In total, 22 individuals (12 patients who underwent FebriDx testing and 10 HCPs from general practices that conducted testing) participated in interviews, which were analysed thematically.
Patients and HCPs expressed positive views about use of the test. They felt FebriDx was a useful tool to inform prescribing decisions and provided a visual aid to support shared decision making and appropriate antibiotic use. Most felt it would be feasible to integrate use into routine primary care consultations. Some practical difficulties with blood collection and interpreting results, which impacted on usability, were identified. Some patients' reactions to negative test results suggested the need for better communication alongside use of the test.
FebriDx was perceived as a useful tool to guide antibiotic prescribing and support shared decision making. Initial practical problems with testing and communicating results are potential barriers to use. Training and practice on using the test and effective communication are likely to be important elements in ensuring patient understanding and satisfaction, and successful adoption.
FebriDx是一种一次性使用、无需分析仪的即时检验，通过手指采血样本检测细菌感染标志物（C反应蛋白[CRP]）和病毒感染标志物（抗粘病毒蛋白A[MxA]）。
作为一项更大规模可行性研究的一部分，我们探讨了医疗保健专业人员（HCPs）和患者对于使用FebriDx以安全减少初级保健中用于下呼吸道感染（LRTIs）的抗生素处方的看法。
在英格兰南部进行了远程半结构化定性访谈。
共有22人（12名接受FebriDx检测的患者和10名来自进行检测的全科诊所的HCPs）参与了访谈，并对访谈进行了主题分析。
患者和HCPs对该检测的使用表达了积极看法。他们认为FebriDx是辅助处方决策的有用工具，并且为支持共同决策和合理使用抗生素提供了直观帮助。大多数人认为将其纳入常规初级保健咨询是可行的。发现了采血和解读结果方面的一些实际困难，这些困难影响了其可用性。一些患者对阴性检测结果的反应表明，在使用该检测的同时需要更好地进行沟通。
FebriDx被视为指导抗生素处方和支持共同决策的有用工具。检测和结果沟通方面最初存在的实际问题是使用的潜在障碍。使用该检测的培训和实践以及有效的沟通可能是确保患者理解和满意以及成功采用的重要因素。
